PULSE BIOSCIENCES, INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
PLSE$55.12-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(53,585) | $(42,210) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 512 | 542 |
| Amortization of intangible assets | 666 | 665 |
| Stock-based compensation | 13,586 | 7,181 |
| Loss on disposal of fixed assets | 6 | 13 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (403) | (65) |
| Other receivables | 48 | 109 |
| Right-of-use assets | 923 | 806 |
| Other long-term assets | (31) | — |
| Accounts payable | (201) | 263 |
| Accrued expenses | 3,212 | 1,219 |
| Lease liabilities | (1,076) | (896) |
| Accrued interest on related party note payable | — | (668) |
| Net cash used in operating activities | (36,343) | (33,041) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (125) | (121) |
| Net cash used in investing activities | (125) | (121) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 478 | 395 |
| Proceeds from exercises of warrants | 49,424 | 14,828 |
| Proceeds from exercises of stock options | 871 | 1,171 |
| Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs | 59,649 | — |
| Issuance cost in relation to related party note extinguishment | — | (6) |
| Deferred issuance costs in relation to future at-the-market equity offering | (281) | — |
| Net cash provided by financing activities | 110,141 | 16,388 |
| Net increase (decrease) in cash and cash equivalents | 73,673 | (16,774) |
| Cash and cash equivalents at beginning of period | 44,365 | 61,139 |
| Cash and cash equivalents at end of period | $118,038 | $44,365 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Rights offering deemed pro-rata distribution to shareholders | $47,700 | $— |
| Principal and accrued interest of related party note settled via issuance of common stock | $— | $(65,249) |
| Right-of-use asset obtained in exchange for lease liability | $830 | $— |
| Other receivable from exercise of warrants | $92 | — |
| Equipment purchases included in accounts payable and accrued expenses | $26 | $— |
| Rights offering and warrant issuance costs in accounts payable and accrued expenses | $13 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.